晚期肾细胞癌：采用异种免疫核糖核酸治疗及适当的手术切除。

Advanced renal cell carcinoma: treatment with xenogeneic immune ribonucleic acid and appropriate surgical resection.

作者信息

Skinner D G, Dekernion J B, Brower P A, Ramming K P, Pilch Y H

出版信息

J Urol. 1976 Mar;115(3):246-50. doi: 10.1016/s0022-5347(17)59158-2.

Abstract

Herein we describe the first clinical treatment of renal cell carcinoma in humans with xenogeneic immune ribonucleic acid. Twelve patients with advanced renal cell carcinoma have been treated by appropriate operations to remove tumor bulk followed by specific passive immunotherapy. Xenogeneic specific immune ribonucleic acid was prepared from the spleen of normal sheep that had received 4 weekly injections of a homogenate of renal cell carcinoma. Results indicate that 1) xenogeneic specific immune ribonucleic acid can safely be given to humans without local or systemic toxicity, 2) there is a suggestion of clinical benefit, since only 2 patients have had progression of known metastases during treatment with immune ribonucleic acid and 3) xenogeneic immune ribonucleic acid can enhance the immune response to renal cell carcinoma, as demonstrated by in vitro lymphocytoxicity tests.

摘要

在此，我们描述了用异种免疫核糖核酸对人类肾细胞癌进行的首次临床治疗。12例晚期肾细胞癌患者接受了适当手术以切除大部分肿瘤，随后进行特异性被动免疫治疗。异种特异性免疫核糖核酸是从正常绵羊的脾脏中制备的，这些绵羊每周接受4次肾细胞癌匀浆注射。结果表明：1）异种特异性免疫核糖核酸可以安全地给予人类，无局部或全身毒性；2）有临床获益的迹象，因为在免疫核糖核酸治疗期间只有2例患者已知转移灶有进展；3）如体外淋巴细胞毒性试验所示，异种免疫核糖核酸可增强对肾细胞癌的免疫反应。